Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	NSCLC, Melanoma, all solid tumors except CRC	IV	CTNO155X2101 An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors	Dr Daniel Tan	NCT03114319	Open
2	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CPDR001C2101 Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients	Dr Daniel Tan	NCT03064854	Open
3	All Solid Tumour	documented RET infusion	LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Dr Daniel Tan	NCT03157128	Open
4	NSCLC, Pancreas and all solid tumors	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
5	NSCLC	with documented EGFR Exon 20 insertion mutation	CLN-081-001 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Dr Daniel Tan	NCT04036682	Open
6	All Solid Tumour	documented RET infusion	LIBRETTO-201 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation	Dr Daniel Tan	NCT03906331	Open
7	All Solid Tumour	Advanced recurrent	THOR-707-101 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors	Dr Tira Tan	NCT04009681	Open
8	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
9	NSCLC, CRC	Advanced recurrent	CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Daniel Tan	NCT04699188	Open
10	NSCLC	Advanced recurrent	DESTINY-Lung03 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Dr Stephanie Saw	NCT04686305	On hold
11	NSCLC	Advanced recurrent	Bayer 21607 An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Dr Daniel Tan	NCT05099172	Open
12	NSCLC	Advanced recurrent	BLU-945-1101 A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer	Dr Daniel Tan	NCT04862780	On hold
13	Cholangio and all soild tumors	with FGFR2 mutation	RLY-4008-101 A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Cancers	Dr David Tai	NCT04526106	Open
14	NSCLC HNSCC Urothelial	Advanced recurrent	BAYER 21343 An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors	Dr Daniel Tan	NCT04999202	Open
15	Breast and Gastric	with HER2+	GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS	Dr Tira Tan	NCT03448042	Open
16	NPC	Recurrent / Metastatic	VT3996-301 An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma	Dr Darren Lim	NCT05166577	Open
17	Sarcoma (Lipo-sarcoma except ddLPS, undifferentiated pleo-mophic sarcoma, myxofibro-sarcoma, synovial sarcoma and leimyo sarcoma	TP53 Wild type	BI 1403-0002 A phase 1a/1b, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091(ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors.	Dr Darren Lim	NCT03964233	Open
18	HCC	Advanced recurrent	SCG 101-UR-103 A Phase I/ IIa, single arm, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05417932	Open
19	HCC (positive GPC3 expression )	Recurrent/ Metastatic	TCD17240 A Phase 1/2 open-label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR444200-based regimen in participants with advanced solid tumors	Dr Darren Lim	NCT05450562	Open
20	All solid tumours	KRAS G12Cmut	CJDQ443E12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Stephanie Saw	NCT05358249	Open
21	All solid tumours	Prior IO responders	BAYER 21820 First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors	Dr Tira Tan	NCT05537740	Open
22	NSCLC & HNSCC	KRAS G12Cmut	BGB-A317-A445-101 Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination with the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Dr Stephanie Saw	NCT04215978	Open
23	HCC	1st line HCC	BMS CA224-106 A Phase 1/2, Safety Confirmation and Double-Blind, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)	Dr David Tai	NCT05337137	Open
24	Breast and other solid tumours (excluding CRC)	PIK3CA H1047R mut	LOXO-PIK-21001 A study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid	Dr Tira Tan	NCT05307705	Open
25	All solid tumors & Stage B/C HCC	MYC oncogene	OTX-2002-101 A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor	Dr David Tai	NCT05497453	Open
26	All solid tumours	KRAS G12Cmut	RMC-6291-001 Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	Dr Daniel Tan	NCT05462717	Open
27	NSCLC, GC/GEJ adenocarcinoma and all solid tumours	EGFR/c-MET amplification	MCLA-129-CL01 Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC	Dr Justina Lam	NCT04868877	Open
28	NSCLC ESCC RCC HNSCC (HPV +ive)	Advanced recurrent	CQEQ278A12101 A phase I/Ib, open-label, multi-center, study of QEQ278 in patients with advanced solid tumors	Dr Justina Lam	NCT05462873	Open
29	NSCLC, PDAC and GC	Advanced recurrent	EBC-129-01 A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours	Dr Matthew Ng	NCT05701527	Open
30	All Solid Tumour	Dose finding cohort: loss of SMARCA4 Backfill cohort: NSCLC with driver mutations in oncogenes (e.g., EGFR, MET, RET, ALK, BRAF, KRAS, ROS1, etc).	PRT3645-01 Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants with Select Advanced or Metastatic Solid Tumors	Dr Tira Tan	NCT05538572	Open
31	Phase 1b (Dose Expansion): Cohorts 1 and 2: Patients with documented HER2 Tyrosine Kinase Domain (TKD) mutation positive NSCLC Cohort 3: Patients with documented HER2 Non-TKD mutation positive NSCLC	Advanced recurrent	BI 1479-0001 An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations	Dr Aaron Tan	NCT04886804	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Bladder	Adjuvant	BO42843 A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Dr Ravindran Kanesvaran	NCT04660344	Open
2	Breast	Mets TNBC	BEXMET Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype	Dr Elaine Lim	NCT04664829	Open
3	Breast	HER2+ Adj	WO42633-Astefania: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy	Dr Yap Yoon Sim	NCT04873362	Open
4	Breast	HER2 +	DESTINY-Breast05: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy	Dr Tira Tan	NCT04622319	Open
5	Breast	Mets TNBC	TROPION Breast02 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Dr Rebecca Dent	NCT05374512	Open
6	Breast	Mets ER+PR+	LaPemERLA Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study	Dr Yap Yoon Sim	NCT05286437	Open
7	Breast	Mets ER+PR+	ELEVATE A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors	Dr Elaine Lim	NCT05181033	Open
8	Colorectal	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
9	Colorectal	Advance 2nd line	Mirati 849-010/KRYSTAL-10 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Dr Dawn Chong	NCT04793958	Open
10	Colorectal	ADVANCED/ METASTATIC	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer	Dr Koo Si-Lin	NCT05425940	Open
11	Esophageal	Metastasis 1st line	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	Dr Justina Lam	NCT04949256	Open
12	Gastric GEJ	Advanced 2nd line	DS8201-A-U306 A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen	Dr Matthew Ng	NCT04704934	Open
13	Gastric GEJ	Advanced 2nd and 3rd line	ASPEN-06 A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT05002127	Open
14	Gastric GEJ	Advance 1st line	FORTITIUDE-101 A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression	Dr Matthew Ng	NCT05052801	Open
15	GEA	Advance 1st line	ZWI-ZW25-301 A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Dr Matthew Ng	NCT05152147	Open
16	Gastric GEJ	Advance 1st line	FORTITUDE-102 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Dr Matthew Ng	NCT05111626	Open
17	Liver cancer or Colorectal cancer with liver metastases	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
18	Liver	Locally advanced	AHCC09 A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05377034	Open
19	Liver	Resectable HCC (high risk of recurrence)	AHCC12 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)	Dr Toh Han Chong	NCT05516628	Open
20	Lung	Mets NSCLC	KRYSTAL-12 A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	Dr Ang Mei Kim	NCT04685135	Open
21	Lung	Adjuvant NSCLC	ADAURA2 A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection	Dr Stephanie Saw	NCT05120349	Open
22	Lung	Mets NSCLC	HERTHENA–Lung02 A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy	Dr Darren Lim	NCT05338970	Open
23	Lung	Mets NSCLC	BGB-LC-201 A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents With or Without Chemotherapy in Patients with Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Dr Darren Lim	NCT05635708	Open
24	Lung	Mets NSCLC	SOS-1 / IIT-SIN-S1-2022-001 A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR mutant NSCLC	Dr Darren Lim	NCT05773092	Open
25	Lung	Mets NSCLC	A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)	Dr Daniel Tan	NCT05801029	Open
26	Lymphoma	Relapsed/Refractory EBV+ Lymphomas	VT3996-202 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)	Dr Nagavalli Somsundaram	NCT05011058	Open
27	Lymphoma	Relapsed/Refractory CLL/SLL	LOXO-BTK-20022 Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)	Dr Eileen Poon	NCT04965493	Open
28	Lymphoma	Relapsed/ Refractory B-cell lymphoma	MK2140-006 A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies	Dr Tan Ya Hwee	NCT05458297	Open
29	Lymphoma	Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	MK1026-008 A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations	Dr Nagavalli Somasundaram	NCT05624554	Open
30	Melanoma	Metastatic/ Unresectable	HBI-8000-303 A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors	Dr Valerie Yang	NCT04674683	Open
31	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN03 - AT148003 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675294	Open
32	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN04 - AT148004 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675333	Open
33	NPC	Metastatic, 3rd line	SG-AAA-II-01 / CAAA601A0SG01T A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in	Dr Daniel Tan	NCT05198479	Open
34	Ovarian	Neoadjuvant	MK4830-002 A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer	Dr Chay Wen Yee	NCT05446870	Open
35	Pancreas	Metastatic, any line	LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients	Dr Joycelyn Lee	NCT05929885	Open
36	Prostate	Metastatic	Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH	Dr Ng Quan Sing	NCT04597125	Open
37	Renal	Locally advanced / metastatic - 1st line	D5086C00001 (SAMETA): A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)	Dr Ravindran Kanesvaran	NCT05043090	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	CLDK378A2X01B An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Dr Daniel Tan	NCT02584933	Open
2	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	LOXO-TRK-15002 (NAVIGATE) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors	Dr Daniel Tan	NCT02576431	Open
3	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
4	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
5	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
6	SOLID TUMORS	ADVANCED/ METASTATIC - 2nd Line	STCC-01 A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers	Dr Daniel Tan	NCT04946968	Open
7	SOLID TUMORS	ADVANCED/ METASTATIC	Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations	Dr Joanne Ngeow	NCT04924075	Open

Current Clinical Trials

​For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

Current clinical trials by body parts

General

For enquiries, please email clinical.trials@nccs.com.sg